RYDAPT-25mg. (Midostaurin Capsule) 25mg

RYDAPT 25mg capsules contain midostaurin, a prescription medicine used in certain blood cancers. It is taken by mouth as directed by a healthcare provider. Suitable for adults and some pediatric patients under supervision.

Strength

25mg

Pack Size

112s

Storage

Ambient

Manufacturer / TM Owner

Novartis

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Midostaurin is prescribed for adults with newly diagnosed acute myeloid leukemia that has a specific genetic mutation called FLT3. It is also used to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia. This medication targets abnormal signals in cancer cells to help control disease progression.

Side Effects

Midostaurin works by interfering with signals that promote cancer cell growth. Patients may notice improved blood counts or reduced symptoms over time. Regular monitoring is important to assess how the body responds to the treatment.

Precautions & Warnings

Keep capsules in their original blister pack until use. Store at room temperature away from moisture and heat. Always handle with dry hands and avoid crushing or opening capsules. Do not take if you are pregnant or breastfeeding without medical advice.

Avoid Interactions

Midostaurin may interact with strong CYP3A4 inhibitors or inducers, such as certain antifungals or anticonvulsants. Grapefruit products can affect how the drug is processed. Discuss all medications, including over-the-counter and herbal products, with your healthcare provider before starting midostaurin.

Frequently Asked Questions

Midostaurin is used to treat certain types of blood cancers, including acute myeloid leukemia with a FLT3 mutation and aggressive systemic mastocytosis.

Store midostaurin capsules at room temperature in their original blister pack, away from moisture and heat.

Midostaurin may interact with other drugs. Always inform your healthcare provider about all medications you are taking before starting midostaurin.

Midostaurin may harm an unborn baby. Do not take it if you are pregnant or breastfeeding without consulting your doctor.

Avoid grapefruit products and consult your doctor before taking any new medications, including over-the-counter or herbal supplements.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.